These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 7107099)

  • 1. Effects of diphenylhydantoin on killer cell activity and other immunological functions. A sequential study including the interaction of Corynebacterium parvum in melanoma patients.
    Thatcher N; Wan HH; Swindell R; Wilkinson PM; Crowther D
    Int J Immunopharmacol; 1982; 4(3):167-74. PubMed ID: 7107099
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of Corynebacterium parvum and BCG therapy on immune parameters in patients with disseminated melanoma. A sequential study over 28 days. II. Changes in non-specific (NK, K and T cell) lymphocytoxicity and delayed hypersensitivity skin reactions.
    Thatcher N; Swindell R; Crowther D
    Clin Exp Immunol; 1979 Feb; 35(2):171-9. PubMed ID: 312169
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of repeated Corynebacterium parvum and BCG therapy on immune parameters: a weekly sequential study of melanoma patients. I. Changes in non-specific (NK, K and T cell) lymphocytotoxicity, peripheral blood counts and delayed hypersensitivity reactions.
    Thatcher N; Swindell R; Crowther D
    Clin Exp Immunol; 1979 May; 36(2):227-36. PubMed ID: 314367
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of Corynebacterium parvum and BCG therapy on immune parameters in patients with disseminated melanoma a sequential study over 28 days. I. Changes in blood counts, serum immunoglobulins and lymphoid cell populations.
    Thatcher N; Swindell R; Crowther D
    Clin Exp Immunol; 1979 Jan; 35(1):36-44. PubMed ID: 428146
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of BCG and Corynebacterium parvum on immune reactivity in melanoma patients.
    Thatcher N; Crowther D
    Dev Biol Stand; 1977 Apr 13-15; 38():449-53. PubMed ID: 608536
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of repeated Corynebacterium parvum and BCG therapy on immune parameters: a weekly study of melanoma patients II. Changes in serum immunoglobulins and lymphoid cell subpopulations.
    Thatcher N; Swindell R; Crowther D
    Clin Exp Immunol; 1979 Jun; 36(3):456-64. PubMed ID: 487647
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of Corynebacterium parvum on cellular immunity of cancer patients, assayed sequentially over 63 days.
    Thatcher N; Lamb B; Swindell R; Crowther D
    Cancer; 1981 Jan; 47(2):285-90. PubMed ID: 7459817
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of intravenous corynebacterium parvum on peripheral-blood effector cells of cancer patients.
    Gill PG; Waller CA; MacClennan IC; Morris PJ
    Br J Cancer; 1980 May; 41(5):782-9. PubMed ID: 7426303
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lack of effect of immunotherapy with BCG and Corynebacterium parvum on hepatic drug hydroxylation in man.
    Wan HH; Thatcher N; Mullen PW; Smith GN; Wilkinson PM
    Br J Cancer; 1979 Apr; 39(4):441-4. PubMed ID: 444399
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alteration in natural defense activity against NK-susceptible B16 melanoma cells after treatment with Corynebacterium parvum.
    Karashima A; Taniguchi K; Yoshikai Y; Nomoto K
    Immunobiology; 1991 Aug; 182(5):414-24. PubMed ID: 1916884
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Activation of peritoneal lymphocyte cytotoxicity in patients with ovarian cancer by intraperitoneal treatment with Corynebacterium parvum.
    Lichtenstein A; Berek J; Bast R; Spina C; Hacker N; Knapp RC; Zighelboim J
    J Biol Response Mod; 1984 Aug; 3(4):371-8. PubMed ID: 6541243
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of Corynebacterium parvum therapy on immunoglobulin class and IgG subclass levels in cancer patients.
    James K; Clunie GJ; Woodruff MF; McBride WH; Stimson WH; Drew R; Catty D
    Br J Cancer; 1975 Sep; 32(3):310-22. PubMed ID: 61040
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Regulation of natural killer cell activation: implementation for the control of tumor metastasis.
    Hanna N
    Nat Immun Cell Growth Regul; 1983-1984; 3(1):22-33. PubMed ID: 6235447
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunomodulation of NK and ADCC by Corynebacterium parvum in acute myeloid leukaemia patients.
    Hokland P; Ellegaard J
    Leuk Res; 1985; 9(1):175-84. PubMed ID: 3857405
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Monitoring natural killer cell activity in the blood of patients with malignant pleural effusion after intrapleural administration of Corynebacterium parvum].
    Marel M; Pospísil M; Fiserová A; Melínová L; Skácel Z; Bednár M
    Cas Lek Cesk; 1990 Apr; 129(16):498-500. PubMed ID: 2340567
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Surgical adjuvant therapy of malignant melanoma with corynebacterium parvum.
    Hilal EY; Pinsky CM; Hirshaut Y; Wanebo HJ; Hansen JA; Braun DW; Fortner JG; Oettgen HF
    Cancer; 1981 Jul; 48(2):245-51. PubMed ID: 7016302
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Suppression of natural killer cell cytotoxicity by splenocytes from Corynebacterium parvum-injected, bone marrow-tolerant, and infant mice.
    Savary CA; Lotzová E
    J Immunol; 1978 Jan; 120(1):239-43. PubMed ID: 342602
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-T antibody in malignant melanoma patients. Influence of response and survival following chemotherapy--changes in serum levels following C parvum, BCG immunization.
    Thatcher N; Hashmi K; Chang J; Swindell R; Crowther D
    Cancer; 1980 Sep; 46(6):1378-82. PubMed ID: 7417939
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low natural-killer-cell activity in familial melanoma patients and their relatives.
    Hersey P; Edwards A; Honeyman M; McCarthy WH
    Br J Cancer; 1979 Jul; 40(1):113-22. PubMed ID: 314301
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Natural killer inhibitory substance produced by the peritoneal cells of patients with ovarian cancer.
    Lichtenstein AK; Berek J; Zighelboim J
    J Natl Cancer Inst; 1985 Feb; 74(2):349-55. PubMed ID: 3856049
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.